Capricor's DMD cell therapy Deramiocel heads to FDA advisory panel

Capricor Therapeutics has confirmed that the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) will convene on 29 July 2026 to review the company's Biologics License Application for Deramiocel, an allogeneic cell therapy for Duchenne muscular dystrophy. The PDUFA target action date remains 22 August 2026, keeping Capricor on course for a potential approval decision before the end of summer.

Deramiocel consists of cardiosphere-derived cells that the company says act by secreting exosomes, which in turn reprogram macrophages away from a pro-inflammatory state and toward a tissue-repair phenotype. The BLA is anchored by data from the Phase 2 HOPE-2 trial, its long-term open-label extension, and the Phase 3 HOPE-3 trial. Capricor reported that HOPE-3 met its primary endpoint using the PUL v2.0 upper-limb function scale, reached statistical significance on the key secondary cardiac endpoint of left ventricular ejection fraction, and cleared all other Type I error-controlled secondary endpoints.

Clinical evidence and regulatory designations

Linda Marbán, chief executive of Capricor, said the company has "confidence in the totality of evidence supporting Deramiocel, which has demonstrated clinically meaningful, statistically significant skeletal and cardiac benefits with a consistent safety profile." Deramiocel carries an unusually dense stack of regulatory designations: Orphan Drug from both the FDA and EMA, Regenerative Medicine Advanced Therapy (RMAT), Advanced Therapy Medicinal Product (ATMP) in Europe, and Rare Pediatric Disease Designation. The last of these could qualify Capricor for a Priority Review Voucher on approval, a tradeable asset that has recently changed hands for over $100 million, representing a potentially significant non-dilutive source of capital.

Advisory committee meetings in rare disease, particularly for novel modalities such as cell therapy, do not always predict the agency's final decision, but they shape public and clinical perception of the evidence base. For DMD specifically, the FDA has previously shown willingness to act on accelerated or conditional pathways, having approved several exon-skipping and stop-codon readthrough therapies in recent years under accelerated approval. Deramiocel's cardiac-targeting mechanism represents a mechanistically distinct approach to the condition, which affects approximately 15,000 individuals in the United States and for which no curative therapy yet exists.

Market context and competitive landscape

The DMD treatment landscape has become increasingly crowded over the past decade. Sarepta Therapeutics remains the dominant commercial player, with multiple approved exon-skipping drugs and the gene therapy SRP-9001 (delandistrogene moxeparvovec). Solid Biosciences and several academic programmes are pursuing additional gene-therapy approaches. Deramiocel's differentiation lies in its cardiac and skeletal muscle preservation mechanism rather than dystrophin restoration, positioning it as potentially complementary rather than directly competitive with approved agents, a framing that may ease the committee's path.

Should the CTGTAC vote in favour and the FDA proceed to approval, Capricor would become one of a small number of cell therapy developers to reach commercialisation in a rare neuromuscular indication. The company noted a parallel litigation with Nippon Shinyaku and NS Pharma in its cautionary disclosures; the outcome of that dispute could affect distribution arrangements. The advisory committee meeting will be available for live streaming, with the FDA typically publishing briefing documents in advance.